Common Contracts
2 similar Exclusive License Agreement contracts by Denali Therapeutics Inc.
EXCLUSIVE LICENSE AGREEMENT BETWEEN GENENTECH, INC. AND DENALI THERAPEUTICS INC. AS OF JUNE 17, 2016Exclusive License Agreement • November 13th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement (“Agreement”) is made and entered into as of the 17th day of June, 2016 (the “Effective Date”) by and between Denali Therapeutics Inc., a Delaware corporation with a principal place of business at 201 Gateway Blvd., South San Francisco, CA 94080 (“Denali”) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“Genentech”). Denali and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.”
EXCLUSIVE LICENSE AGREEMENT BETWEEN GENENTECH, INC. AND DENALI THERAPEUTICS INC. AS OF JUNE 17, 2016Exclusive License Agreement • October 27th, 2017 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This Exclusive License Agreement (“Agreement”) is made and entered into as of the 17th day of June, 2016 (the “Effective Date”) by and between Denali Therapeutics Inc., a Delaware corporation with a principal place of business at 201 Gateway Blvd., South San Francisco, CA 94080 (“Denali”) and Genentech, Inc., a Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“Genentech”). Denali and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.”
